Ondansetron (Zofran) 32 mg, single intravenous (IV) dose: Product removal due to potential for serious cardiac risks

0

Intravenous news: The FDA report “FDA is notifying health care professionals that the 32 mg, single intravenous (IV) dose of the anti-nausea drug Zofran (ondansetron hydrochloride) will no longer be marketed because of the potential for serious cardiac risks.”

Main page

Share.

Comments are closed.